Results

Retatrutide Reported Results

Efficacy and tolerability endpoints as reported in trial publications and sponsor disclosures. Values appear here only once verified against their source document.

Efficacy

Latest Verified Phase 3 Result

TRIUMPH-2 · NCT05929079

-20.8%

Mean change in body weight

Retatrutide 12 mg · 80 weeks · Adults with type 2 diabetes and obesity or overweight · Efficacy estimand

Peer-reviewed Phase 3

What this means

A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.

Figure / record sourceLast verified 30 Sept 2026

Peer-reviewed publicationLast verified 13 Oct 2026

All verified results →

Results Explorer

Retatrutide Results Explorer

Filter verified efficacy endpoints by trial, dose, endpoint and treatment duration. Only values verified against an official source document are shown.

Trial

Dose

Endpoint

Treatment duration

Results from different trials should not be compared directly because populations, study designs, treatment durations, endpoints and analysis methods may differ.

Showing 6 of 29 verified results

Download all verified results (CSV)

TRIUMPH-4NCT05931367
Change in WOMAC pain score (baseline 6.0)
-4.4 points
Dose
12 mg
Duration
68 weeks
Population
Adults with obesity or overweight and knee osteoarthritis without diabetes
Estimand
Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Change in WOMAC pain score (baseline 6.0)
-4.5 points
Dose
9 mg
Duration
68 weeks
Population
Adults with obesity or overweight and knee osteoarthritis without diabetes
Estimand
Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Change in WOMAC pain score (baseline 6.0)
-2.4 points
Dose
Placebo
Duration
68 weeks
Population
Adults with obesity or overweight and knee osteoarthritis without diabetes
Estimand
Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Mean change in body weight
-28.7%
Dose
12 mg
Duration
68 weeks
Population
Adults with obesity or overweight and knee osteoarthritis without diabetes
Estimand
Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Mean change in body weight
-26.4%
Dose
9 mg
Duration
68 weeks
Population
Adults with obesity or overweight and knee osteoarthritis without diabetes
Estimand
Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Mean change in body weight
-2.1%
Dose
Placebo
Duration
68 weeks
Population
Adults with obesity or overweight and knee osteoarthritis without diabetes
Estimand
Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026

Trial	Endpoint	Dose	Duration	Population	Estimand	Value	Source
TRIUMPH-4NCT05931367	Change in WOMAC pain score (baseline 6.0)	12 mg	68 weeks	Adults with obesity or overweight and knee osteoarthritis without diabetes	Efficacy estimand	-4.4 points	Sponsor topline result What this means The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367	Change in WOMAC pain score (baseline 6.0)	9 mg	68 weeks	Adults with obesity or overweight and knee osteoarthritis without diabetes	Efficacy estimand	-4.5 points	Sponsor topline result What this means The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367	Change in WOMAC pain score (baseline 6.0)	Placebo	68 weeks	Adults with obesity or overweight and knee osteoarthritis without diabetes	Efficacy estimand	-2.4 points	Sponsor topline result What this means The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367	Mean change in body weight	12 mg	68 weeks	Adults with obesity or overweight and knee osteoarthritis without diabetes	Efficacy estimand	-28.7%	Sponsor topline result What this means The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367	Mean change in body weight	9 mg	68 weeks	Adults with obesity or overweight and knee osteoarthritis without diabetes	Efficacy estimand	-26.4%	Sponsor topline result What this means The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367	Mean change in body weight	Placebo	68 weeks	Adults with obesity or overweight and knee osteoarthritis without diabetes	Efficacy estimand	-2.1%	Sponsor topline result What this means The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026

Weekly Briefing

The Retatrutide Report

The most important retatrutide developments, once a week.

Clinical trial changes
New PubMed research
FDA / EMA regulatory developments
Eli Lilly announcements
Major efficacy and safety updates

No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.